Security key
16385C104
Chemomab Therapeutics Ltd. - Ordinary Shares / American Depositary Shares (CMMB)
CUSIP: 16385C104
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Ordinary Shares / American Depositary Shares
- Total 13F shares
- 4,160,723
- Total 13F value
- $7,530,756
- Share change
- -395,644
- SEC-reported price per share
- $1.81
- Number of holders
- 16
- Value change
- -$700,297
- Number of buys
- 4
- Number of sells
- 10
- Shares outstanding
- 412,914,375
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
16
Top holders
10
CMMB full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Chemomab Therapeutics Ltd. SEC filings
Chemomab Therapeutics Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 16385C104
Recent filing periods:
Ownership snapshot
Top reported holders of CMMB - Chemomab Therapeutics Ltd. - Ordinary Shares / American Depositary Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Sep 2024
13F
Lead comparable stake: 0.42%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 0.42%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
0.42%
SPHERA FUNDS MANAGEMENT LTD.
0.29%
Yelin Lapidot Holdings Management...
0.2%
MORGAN STANLEY
0.1%
Ikarian Capital, LLC
0.05%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
0.42%
|
$2,733,799
1,741,273 shares
|
— | 30 Sep 2024 |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
Company
|
0.29%
|
$1,906,883
1,214,575 shares
|
— | 30 Sep 2024 |
| Yelin Lapidot Holdings Management Ltd. |
13F
Company
|
0.2%
|
$1,271,256
809,717 shares
|
— | 30 Sep 2024 |
| MORGAN STANLEY |
13F
Company
|
0.1%
|
$631,567
402,272 shares
|
— | 30 Sep 2024 |
| Ikarian Capital, LLC |
13F
Company
|
0.05%
|
$335,025
213,392 shares
|
— | 30 Sep 2024 |
| TWO SIGMA SECURITIES, LLC |
13F
Company
|
0.01%
|
$62,704
39,939 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
16
Shares
4,160,723
Rows available
16
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
15
Q4 2024 holders
16
Holder diff
1
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend